SD BioSensor, Inc.

Although merger and acquisition activity in the South Korean biopharma sector is viewed as relatively timid compared to the global market, it seems to have increased notably since the end of the COVID

Biopharma Acquisitions Biopharma merger and acquisition value for the third quarter of 2022 reached $15.4bn from 41 transactions, 21 of which had disclosed values. Four M&A transactions hit or exceede

Meridian Bioscience, Inc. said on 7 July it will be acquired by SD BioSensor, Inc. and SJL Partners in an all-cash deal valued at $1.53bn. “In addition to delivering immediate and significant value

US consumers are being told to avoid several COVID-19 tests that have reached market without the sanction of the Food and Drug Administration. In separate notifications issued March 1, the agency said